Effect of CYP2D6*4, CYP2D6*10 polymorphisms on the safety of treatment with timolol maleate in patients with glaucoma

Frequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across Europe

(2019) Jelena Petrović et al.   EUROPEAN JOURNAL OF HUMAN GENETICS

Association Between the Lower Extremity Deep Venous Thrombosis, the Warfarin Maintenance Dose, and CYP2C9*3, CYP2D6*10, and CYP3A5*3 Genetic Polymorphisms: A Case–Control Study

(2017) Shang Ju et al.   Genetic Testing and Molecular Biomarkers

Cytochrome P450 2D6 Phenoconversion Is Common in Patients Being Treated for Depression

(2013) Sheldon H. Preskorn et al.   JOURNAL OF CLINICAL PSYCHIATRY

Association of CYP2D6 Single-Nucleotide Polymorphism with Response to Ophthalmic Timolol in Primary Open-Angle Glaucoma—A Pilot Study

(2010) Hongzhi Yuan et al.   JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Cytochrome Oxidase 2D6 Gene Polymorphism in Primary Open-Angle Glaucoma With Various Effects to Ophthalmic Timolol

(2009) Yangfan Yang et al.   JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Is the medication used to achieve the target intraocular pressure in glaucoma therapy of relevance? – An exemplary analysis on the basis of two beta-blockers

(2009) Matthias C. Grieshaber et al.   PROGRESS IN RETINAL AND EYE RESEARCH